arrow_back Back to App

Home Infusion for Alpha-1 Antitrypsin Deficiency: New Medicare Coverage

This new act expands Medicare coverage to include home-based treatment for Alpha-1 Antitrypsin Deficiency. This means eligible individuals with this condition can receive necessary infusion therapy at home, improving access to care and potentially reducing financial burdens.
Key points
Medicare Part B will now cover Alpha-1 Antitrypsin Deficiency Disorder treatment (augmentation therapy) furnished in an individual's home.
The act also includes payment for intravenous administration kits and up to 2 hours of nursing services for home infusion therapy.
These changes take effect on January 1, 2023, for individuals enrolled in both Medicare Parts A and B, not in a Medicare Advantage plan.
article Official text account_balance Process page
Expired
Citizen Poll
No votes cast
Additional Information
Print number: 117_HR_7346
Sponsor: Rep. Salazar, Maria Elvira [R-FL-27]
Process start date: 2022-03-31
Lustra uses Artificial Intelligence. Verify details in source documents.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch

OFFICIAL LEGAL TITLE

John W. Walsh Alpha-1 Home Infusion Act of 2022

FREQUENTLY ASKED QUESTIONS

What is the official ID of this bill?

The official print number for this legislation is 117_HR_7346.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-03-31.

What are the main provisions?

Key points include:

  • Medicare Part B will now cover Alpha-1 Antitrypsin Deficiency Disorder treatment (augmentation therapy) furnished in an individual's home.
  • The act also includes payment for intravenous administration kits and up to 2 hours of nursing services for home infusion therapy.
  • These changes take effect on January 1, 2023, for individuals enrolled in both Medicare Parts A and B, not in a Medicare Advantage plan.
What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Salazar, Maria Elvira [R-FL-27].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

CATEGORIES

Health Benefits